New pill takes on advanced cancers in early trial

NCT ID NCT07339748

Not yet recruiting Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking for early signs of tumor shrinkage. About 51 participants will take the pill once daily, and researchers will monitor safety and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZL-85FA tablets (an experimental oral drug)
What this could lead to: If successful, this could point toward a new oral treatment option for certain advanced cancers like breast, ovarian, or prostate cancer.
What could go wrong: This is an early-phase trial with only 51 participants, so it is too soon to know if the drug works. Side effects are unknown, and many early cancer drugs fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma fallopian tube cancer ovarian cancer primary peritoneal carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

The First Affiliated Hospital Of Anhui Medical University

Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.